CytoDyn Inc (QB) (CYDY) News

what we need is a clear timeline to financial catalysts. we need to know which developments will drive an increase in value in our stock, and at least an approximate stab at when. that's how you get investors excited, and that's how you attract new investors. Jay may not think the SP matters, but investors do.

as example, the PR from a week ago talks about "mediating ART-Free Viral Control in Infant Macaques" - and goes on to explain the study in brutal detail the purpose of the study. I've been invested for 8 years and i stopped reading after 3 sentences - what's a potential new investor to do?

What we really need a business-minded CEO, who takes the science from Jay, and packages it for existing and new investors in a way that is easy to understand, and generates buzz around this company. And maybe he/she can strike deals or do something to move the SP.

I remain the camp that at this pace (with the current leadership structure - starting at the top with our wealth manager COB) with the company being run more like a science lab than a business, we are a long, long way from seeing any relief on the SP. I have settled into that, and am not stressing about it any more. But that doesn't mean it's not frustrating.

We are on the brink of a breakout. Watch as other news breaks before Shareholders meeting. Any real investor,,not the paid variety...will acknowledge the solid steps forward after the reorganization. Leronlimab will only continue to attract more investors. The drug is just that good. Get ready for more solid steps forward. The number of long investors is quite amazing for a company in the OTC. I am hearing many good things from all over.
We are exceptionally lucky to have Dr. Jay with all his experience and connections. Even the FDA agrees!
$CYDY$ 2024 and buying more!

Well, I write another post, as long as I am allowed to do so.
What is on my mind is the one percent that we received from the court instead of the full 10 % for damage done to the stock, the company and the share holders.
Who ever was in charge to represent CytoDyn in court negotiations was either meek and weak or not quite honest.
This is just my opinion.
Maybe more next time?

It was a happy sight, when I saw the news article from CytoDyn.
I sought it was about the court settlement, the damage refund they were obligted. to pay for the damages done to CYDY.
But instead it was a long story about our current stock status. After i finished reading, I was kind of bored.
It was about next years progress of any improvement and filing with FDA,
The market did think it was anything great, the stock did not make any move up.

The stock holders are keeping CYDY in place.

CYDY will go up. We have a lot of meaningful/knowledgeable posters. Don't reply to me, stay on topic.
Chump

When will Nader get his next felony conviction? He can't keep delaying his trial forever.

Apparently you suffer from the same syndrome. You make claims without evidence.

If you know so much spout it out because roght now you have given zero facts,but pretend to know a lot.

Let me tell you what's wrong with this board, in case you do not know.

If I paraphrase some fact, all the ******* here jump on me to prove it.

If I show the real facts by copying the information, verbatim, all the ******* here jump on it showing it has no bearing because this company/board/officers/experts
don't care, get paid too much, not qualified yada yada yada.

Basically, if I find interesting information on Max, do you think I will share it here?

DO YOUR HOMEWORK!

When will you start to do your homework?
"I will be impressed when someone who has actual clinical trial experience with cancer is hired." This tells me only one fact - your showing me what you
don't know, and, at the same time, spouting misinformation. Stop it.

Gilead gives up on $15M MASH bet with Yuhan after mulling preclinical data

Now this is interesting 🤔 🤑

https://www.fiercebiotech.com/biotech/gilead-gives-15m-mash-bet-yuhan-after-mulling-preclinical-data

Im not impressed and i know other stockholders feel same. You must be on board. I will be impressed when someone who has actual clinical trial experience with cancer is hired. Do you realize that if you combine everyone that works at cydy have no clinical cancer trials..

Bro what's with the personal attacks? Is that where we are as a community? Seriously reset it my man

You are so uninformed. Who in their right mind would write "People look at his credentials ,and they are not impressed with what he is going to do."

People? Name them.

His hiring just set stock on fire. People look at his credentials ,and they are not impressed with what he is going to do. Be realistic. We need a different pathway. Jow many people have they hired with similar hype.

Dr jay said cancer was our priority. Again,why bring hiv guy on board. Im srill waiting for his big credentials

NOTHING is going on hasn't been for years

Why does anyone think he is hired to help with cancer? Where does it say that? Perhaps he was brought on to help develop long lasting Leronlimab. Perhaps he was brought on to help develop a partnership. People keep acting like they know what is going on. Maybe they should wait until Dr Jay tells everybody what is going on, instead of speculating and pushing the negative agenda. So far, Dr Jay has delivered, is delivering, on his promises. Stay tuned for more good news, clinicals starting up, and exciting new developments!

Ok,tell me what his credentials are. Show me why he is going to help us woth cancer.im waiting

I told you to do a little digging. Are you afraid of homework? Stop refuting his credentials. That would be a good start.

What is point of hiring a hiv assistant professor with one paper.

You need to dig a helluva lot more before making those gigantic leaps.

I thought our focus is on cancer. Dr. Max has written one paper on hiv. He is assistant professor with a do not md. How can he possiibly help us toward cancer trials. He has 0 experience. Jay is touting him like he will save us. I hope im wrong,but i think just another bad hire. Get someone with clinical cancer experience.

The stock is 15 cents you buffoon how much lower can it even go lollllllll. $10 to 15 cents yeah shorts are really hurting. Lol

How many clinical trials has dr. Max completed in cancer.

The oppositions to Leronlimab-CYDY, having a hard time holding the price down. They had to spend millions early this morning to short the stock. The higher the price keeps holding, the more it cost them to keep the stock at a certain level that is allowed .

What a Hoss! CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development

GlobeNewswire - 8 minutes ago Investment News

This dude's got what it takes. So better wake up investors. CytoDyn with Dr. Jay is on a roll that will last for decades.
I am getting it while the getting is good. Do what you want.

CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development

https://www.cytodyn.com/newsroom/press-releases/detail/629/cytodyn-appoints-dr-max-lataillade-as-senior-vice

I dont have problem with ceo living in another state. Deals are made on internet and in person. If a deal comes up ceo can go to either internet or meeting. Im not sure why you think ceo for cydy has enough work for 8 hours a day 5 days a week. No deals,no tests goung,stock not moving,very few people to administer

If a ceo lives 80 miles from the company office in a comfortable home , would he be able to supervise his employees enough to have progress at bringing the studies to the FDA ?
Is it adviseable have the CEO work from his home?
Who is supervising the CEO? He may have another or two jobs on the side?
This is just in case " IF ", and it is just my opinion.

I can appreciate these mouse studies,but the reality is they are years from getting something to market from this info. We need multiple clinica tests on different cancers. We still have not got fda approval on recent submission.

https://www.cytodyn.com/newsroom/press-releases/detail/628/cytodyn-announces-abstract-that-highlights-leronlimabs

The efficacy and safety of leronlimab is truly amazing.

"“These results demonstrate a previously unappreciated synergy between CCR5 blockade and antibody neutralization that opens the door to a new approach for an HIV cure that should be explored further,” said Jonah B. Sacha, Ph.D, Chief of the Pathobiology and Immunology Division at the Oregon National Primate Research Center at Oregon Health & Science University. The study was funded by an NIH grant awarded to OHSU and led by Dr. Nancy Haigwood, Dr. Sacha, and their collaborators.

“We are proud to report these results as we continue to progress our clinical development pipelines for leronlimab across a number of clinical indications,” said Dr. Jay Lalezari, CEO of CytoDyn. “The potential for a treatment path for HIV utilizing leronlimab that allows for long-lasting viral control and potentially reduces or eliminates the need for ongoing ART is a thrilling prospect. We’re grateful to our partners at Oregon Health & Science University and look forward to continuing this important work.”

Dr. Sacha will present the abstract at the 5th annual HIV Research for Prevention Conference in Lima, Peru. Details on the presentation are shown below.

Title: Short-term combination immunotherapy with broadly neutralizing antibodies and CCR5 blockade mediates ART-free viral control in infant rhesus macaques
Presentation Type: Oral abstract session
Session Title: Planet of the Apes: Learning immunogenicity from animal models
Session Date and Time: October 10, 2024, 5:30-7:00PM PET

While I thought it was a great update call with regard to the science (the mouse studies confirming efficacy in MASH, figuring out the dosing, etc.), the issue remains time. How long will it be until we are moving toward generating revenue (or at least deep / late stage into well powered human trials). I still expect it to be years - and that's what we'd need to see for a buyout. especially given that the biotech market has become more sober and discerning about targets (and their progress).

I did think it was disappointing in the call that Jay dismissed the question about the share price. Sure, he can't control it day to day, but the SP is what drives the value of our investment - it was a tone deaf response by him. Also the fact that there was no focus on "increasing shareholder value" in terms of the core objectives of the company. Surely he knows this is first and foremost an investment for us all. These are just examples that point again to the reasons i think he's a great CMO, but a poor CEO.

I remain the camp i would take a $.50 buyout right now - or really anytime in the forseeable future For those who scoff at that, remember, it's over a 3X from here. There's a chance we don't see that for quite some time at the current rate.

I didnt see anywhere we have approval. Why dont they give us this info after approval.

Wow, I missed it this morning. No wonder there is such strong buying. I may have to raise my order.
"“Investigating leronlimab in the field of oncology remains our top priority, and we are excited to further invest in our promising relationship with Syneos Health. With this expanded mandate, we expect to generate clinical data affirming the utility of leronlimab in combination with trifluridine plus tipiracil (TAS-102) and bevacizumab,” said Dr. Jacob Lalezari, CEO.

As previously announced, the Company’s final study protocol was submitted to the FDA for approval in September 2024, and CytoDyn expects to start screening patients in early 2025."

To all those responsible for helping keep the price down all this time... a big shout out! I may treat you all to your favorite Happy Meal before long.
Keep up the Duh Diligence.
$$$CYDY$$$ 2024 Great work Team CytoDyn

https://www.cytodyn.com/newsroom/press-releases/detail/627/cytodyn-engages-syneos-health-as-cro-for-its-phase-ii

Amagawd hammer don't hurt em! Talk about a body slam

Time is money and time is short for all the promises for Leronlimab.
Reading messages, many new trials have been started using Leronlimab for 5 or ten diseases to fight, This is an ambiscion, that is difficult to accomplish in 2024
I am not an expert in in this business, but common sense tells you, that it is easier to just work with one desease that has been tested over and over and provide it to the FDA again to have them concentrate on this, improve the critical items and ask the FDA again,

I’ve given up on explaining to you how damaged you are by your experiences investing in this stock. That being said, calling me a fraud is ridiculous. Find a single fraudulent thing I have ever said. I won’t hold my breath for a retraction even if it is due.

What a "career" for a US Air Force grad. Was he ever a commissioned officer? Really odd for an Air Force grad to make a career out of slinging bs penny stocks.

My comment/IMHO the guy in the video deserves to be investigated then prosecuted to full extent for his major role in the khazempourhassan fraud. That "therapeutic" has NEVER been in U S trial--and appears to be another scam supported by "43" ms hooey fooey sooey--the sheikh of nodderspeak et al.

Why that post is allowed on this board is a reminder , salt/wound of fraud committed by nodder and his paid pumper posters. Chessmaster--the facebook mod--sheikh--gambler--rabbit--chuckles--wolf--ops--drD--pitt--persian--the list goes on. ALL frauds

And suddenly with a NOV trial date so many have gone MIA??

Please watch this and comment your opinion

If leronlimab didn't have game changing potential there would be no paid for banshee warriors trying to discredit the company while shorting and flipping to manipulate the pps. These tactics over time have had there intended results

Never in the history of any penny stock has this been true. What you have experienced is reality. People predicting a stock going down, then seeing it go down is called "reality".
Just perhaps the reason is tied to fraud and lack of any inking of success from the company.

Ever notice all the "missing".?? Now even the thangout mods have jumped ship. Down to poor old riz and mikey. That November trial date scare some of them same as here??

Sure just pure coincidence

Patterson always said... time to start leronlimab for the Fr. Dietrich escaped virus aka China Virus aka Covid-19 was in the mild to moderate stage: Now why was it not given EUA or at least allowed to continue under Right To Try; A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
Harish Seethamraju MD 1, Otto O. Yang MD 2, Richard Loftus MD 3, Onyema Ogbuagu MD 4, Daniel Sammartino MD 5, Ali Mansour MD 1, Jonah B. Sacha PhD 6, Sohita Ojha PhD 6, Scott G. Hansen PhD 6, Arvin Cyrus Arman PhD 7, Jacob P. Lalezari MD 8

•
Leronlimab is an investigational CCR5-specific humanized IgG4 monoclonal antibody.
•
In COVID-19 leronlimab appears to have improved NEWS2 scores compared to placebo.
•
In COVID-19 leronlimab may be associated with fewer AEs compared to placebo.

More studies to be published soon. All eyes will be on leronlimab.

$CYDY$ 2024

The coming miracle medicine is called leronlimab. If leronlimab didn't have game changing potential there would be no paid for banshee warriors trying to discredit the company while shorting and flipping to manipulate the pps. These tactics over time have had there intended results. If leronlimab were not so good, I would not buy more. No matter how this plays until new trials begin, I will continue to add on any dips of consequence. Despite the warrant conversions and selling stock holders, the pps has gained ground from the low a few months ago. Today we see case in point. We are on a gradual choppy uptrend as a result the accomplishments this past year. It will continue as well. Many good things are in store between now and end of year should anyone pay attention to the official company communications.

The latest prospective filed Pursuant to Rule 424(b)(3) yesterday; "The decreases in G&A expenses for the fiscal year ended May 31, 2024, compared to the prior fiscal year, were primarily due to reductions in other, stock-based compensation, salaries, benefits, and other compensation, and legal fees. The decrease in other expenses was primarily the result of a reduction in audit-related fees. The decreases in stock-based compensation and salaries, benefits, and other compensation were primarily related to headcount reductions in an effort by the Company to preserve cash and align resources with corporate priorities. The decrease in legal fees was primarily due to decreased fees related to the SEC and DOJ investigations, offset by less fees covered by the Company’s insurance carrier(s) and increased fees related to the Amarex litigation."

It would be welcome to see continued fiscal belt tightening as in added salary related compensation cuts. The difficulties lie in increasing expenses now that the company is again on the offensive going forward with trials and studies. Anticipate new hires in preparation for these studies and trials.The good thing to expect that will cause a substantial uptick in pps will be the partnerships that provide funds for investigative endeavors and trials. It's coming. Even more will come with the studies and papers that are in the hopper now to come out in print. Hence, more eyes again will focus on leronlimab as the past ghosts of FDA reaction a la Nader fades into the dust bin

So looking forward to the day when even the paid bashers and shorties must admit that leronlimab is truly a miracle drug. Most already know it, but pay daddy says keep bashing. Competition goes to no end to keep out the threats to their bottom line. Leronlimab is not the first and won't be the last, but it will the one that endures to save so many millions of lives. Game changers are always a threat to the status quo. Hang tough because the real science represents the truth and the truth has a way of floating to the top. $$CYDY$$ 2024 and onward.

They’re not letting him do what he said he would! No, all that money is going in their pockets! What the *********!

Did you guys see how management is being paid to do nothing? Lolll hmmm I wonder why anyone would work for this company. Hmmmmmm. That's out of your pockets btw

As stock continues in a downward trend,we need to relieve tanya of her duties. Let jay make some deals and move company forward.

I don't understand. So you are excusing him for the fraud he directed towards the shareholders? Let me ask you, say you went into a restaurant and the health inspector came in and announced the place was being shut down for using dog as their choice of meat. Would you want to stay and eat there anyway?

I do not hate that guy, he knew all the time that the big pharmacies and especielly the FDA would never
allow Leronlimab to be approved, because of the quality of the product.